Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

Trial Profile

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Tisagenlecleucel-T (Primary)
  • Indications Acute lymphoblastic leukaemia; Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 Results assessing the effect of pembrolizumab in combination with (CAR) T cells in patients with relapsed B-ALL from NCT02374333 and NCT02906371 trials (n=4), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results (n=10) assessing effect of CAR-T cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia using patient data from NCT01626495 and NCT02374333 trials, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Sep 2016 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top